Summary:
You are invited to take part in
this study because you have chronic kidney disease (CKD) and high
blood pressure. We are doing this study to learn more about the benefits and
safety of treatment of an experimental drug called baxdrostat in combination
with dapagliflozin for treating patients with CKD and high blood pressure. We
also want to better understand CKD and the health problems that come with it.
Criteria:
Be ≥ 18 years of age
Have an:
- eGFR ≥ 30 and < 60 mL/min/1.73 m2 (local or central laboratory values), AND UACR ≥ 30 mg/g (3.39 mg/mmol) and < 500 mg/g (56.5 mg/mmol) (central laboratory values only) or
- eGFR ≥ 30 and ≤ 75 mL/min/1.73 m2 (local or central laboratory values), AND UACR ≥ 500 mg/g (56.5 mg/mmol) and ≤ 5000 mg/g (565 mg/mmol) or UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local or central laboratory values
- Have history of HTN and a SBP ≥ 130 mmHg (the most recent value within 4 weeks of screening or at the Screening Visit) and ≥ 120 mmHg at the Randomisation Visit.
Be ≥ 18 years of age
Have an:
- eGFR ≥ 30 and < 60 mL/min/1.73 m2 (local or central laboratory values), AND UACR ≥ 30 mg/g (3.39 mg/mmol) and < 500 mg/g (56.5 mg/mmol) (central laboratory values only)
- eGFR ≥ 30 and ≤ 75 mL/min/1.73 m2 (local or central laboratory values), AND UACR ≥ 500 mg/g (56.5 mg/mmol) and ≤ 5000 mg/g (565 mg/mmol) or UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local or central laboratory values
- Must be on Stable and maximum tolerated dose of an ACEi or an ARB (not both) for at least 4 weeks prior to Screening Visit.